Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. rivelin-clo

RIVELIN-CLO SIGNED

The Ultimate Therapy for the Oral Lichen Planus

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RIVELIN-CLO project word cloud

Explore the words cloud of the RIVELIN-CLO project. It provides you a very rough idea of what is the project "RIVELIN-CLO" about.

correct    sensations    revenues    iib    goals    trials    people    painful    disorder    diseases    generate    olp    efficacy    founded    oral    patch    danish    lives    ip    daily    launch    kept    84m    rivelin    damage    toxicity    lesions    hospitals    perspectives    22    alleviation    ways    systemic    immune    employees    chance    cure    afyx    exclusively    chronic    7    launching    mucosa    2h    lack    combined    markets    prevented    options    lower    dosing    approved    treatment    2014    lesion    precancerous    planus    generating    minimization    corticosteroids    ongoing    guarantee    worldwide    usa    normal    electrospinning    first    ultimately    struggle    occlusion    living    clinical    staff    gather    self    saliva    symptoms    treat    bystander    drug    topical    involve    adherence    financial    innovative    commercial    suffering    share    lichen    primary    therapeutic    10m    tissues    international    time    incorporating    reg    market    spread    causing    6m    undesired    patients    potentially    therapeutics    clinics    clobetasol    erosive    venture    mucosal    clo    company    burning   

Project "RIVELIN-CLO" data sheet

The following table provides information about the project.

Coordinator		 AFYX THERAPEUTICS A/S 

Organization address
address: LERGRAVSVEJ 57, 2TV.
city: COPENHAGEN
postcode: 2300
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Denmark [DK]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AFYX THERAPEUTICS A/S DK (COPENHAGEN) coordinator 50˙000.00

Map

 Project objective

Oral lichen planus (OLP) is an immune-related disorder affecting 84M people worldwide (10M in EU and USA). OLP is a chronic condition which can ultimately lead to precancerous lesions, while patients suffering from it may struggle daily with painful and/or burning sensations in the oral mucosa, being thus kept from living their normal lives. Since there is no approved cure for OLP, the primary goals of its treatment are the alleviation of symptoms and the minimization of mucosal damage from erosive lesions. Current therapeutic options involve the use of topical corticosteroids (typically Clobetasol). However, the ways of use available in the market show lack of adherence to the mucosa and there is a high chance that the product is spread to other areas (which results in reduced efficacy and potentially causing undesired topical and systemic side effects). Our Danish company AFYX Therapeutics A/S was founded in 2014 with the aim to develop innovative approaches to treat mucosal diseases such as OLP. We have developed our first product incorporating an innovative technology (using an electrospinning process): the RIVELIN®-CLO patch. It’s the first to have been developed exclusively for the treatment of OLP, and its unique properties include self-adherence to the oral tissues (2h of topical drug application); occlusion of the lesion; lower bystander toxicity (Clobetasol is prevented from being spread by saliva) and the correct dosing every time. Clinical Phase IIb trials of the patch are ongoing with clinics and hospitals across EU and US and through this project we aim to guarantee that RIVELIN®-CLO is a success from a technical, commercial and financial perspectives, before launching it to the international markets. Five years after market launch, we expect to gather 7% of the EU and US combined OLP treatment market share, generating €22.6M revenues to our company and increasing our staff to 40 employees and generate new IP to venture new markets with our technology.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RIVELIN-CLO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RIVELIN-CLO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

MIGRATECH 4.0 (2019)

The revolution in micro-granulation technology for eco-friendly, production efficient, superior ceramic tiles

Read More